Atención médica de calidadDescubra por qué Mayo Clinic es el mejor lugar para atenderse. Pide una cita.
Jithma P. Abeykoon, M.D., is a clinician-investigator in the Division of Hematology in the Department of General Internal Medicine. He cares for people with lymphoma and histiocytic cancers and conducts research in basic, translational and clinical sciences.
His research focuses on understanding and delineating disease biology and discovering new treatment strategies for individuals with aggressive non-Hodgkin lymphoma and histiocytic cancers. Dr. Abeykoon has a special interest in initiating early-phase clinical trials. He brings new and effective treatment strategies from the bench to the bedside for people with blood cancers.
Dr. Abeykoon's basic and translational science research focuses on studying new biological pathways in lymphoma. He discovers new treatment strategies for people with difficult-to-treat cancers. Dr. Abeykoon discovered a new drug combination, CRM1 inhibitor combined with choline salicylate, with antitumor activity. This combination therapy induces homologous recombination repair (HRR) deficiency in HRR-proficient cells by decreasing the expression of RAD51, a critical protein involved in HRR.
Dr. Abeykoon guided these findings from the bench to the bedside with an investigator-initiated phase 1 clinical trial for people with relapsed lymphoma and histiocytic malignancies. Dr. Abeykoon does active research on exploiting other pathways associated with DNA damage and cell proliferation. He strives to bring new and efficacious treatments from the bench to the bedside for early-phase clinical trials.
Infórmate sobre los ensayos clínicos que abordan preguntas científicas específicas sobre la salud humana y las enfermedades.
Explora todos los estudios de investigación en Mayo Clinic.
Ver las conclusiones revisadas por colegas que publiqué como resultado de mi investigación.